Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
New coronavirus infection is an important cause of public health emergencies at home and abroad, which seriously affects people's health and social stability. The outbreak of SRAR-COV in China in 2003 caused serious social impact. From January 2002 to August 7, 2003, there were a total of 8,422 cases worldwide, involving 32 countries and regions, of which 919 cases were fatal, with a fatality rate of nearly 11%. The fatality rate of elderly patients and patients with underlying diseases was even more high.There is no precise and effective treatment for coronavirus infection. In vitro, IFN-α2β has inhibitory effects on MERS-CoV and closely related coronavirus severe acute respiratory syndrome (SARS) -CoV. A study showed the effects of interferon-α2β and ribavirin on the replication of nCoV isolates hCoV-EMC / 2012 in Vero and LLC-MK2 cells. The combined application may be useful for the management of patients with nCoV infection in the future. At present, the combination therapy of interferon α2β and ribavirin has been successfully applied in the initial treatment and prevention of SARS and MERS.The purpose of this study was to evaluate the efficacy and safety of recombinant human interferon α1β in treating patients with new coronavirus infection in Wuhan.
Description: dyspnea
Measure: The incidence of side effects Time: Within 14 days after enrollmentDescription: SPO2≤94%
Measure: The incidence of side effects Time: Within 14 days after enrollmentDescription: respiratory rate ≥24 breaths/min in oxygen state)
Measure: The incidence of side effects Time: Within 14 days after enrollmentDescription: the patient had a normal body temperature of > for 24 hours (without taking antipyretic drugs or hormones) without self-consciousness Dyspnea or reduced dyspnea;
Measure: Time from patient enrollment to clinical remission Time: Within 14 days after enrollmentDescription: Proportion of patients with normal body
Measure: Proportion of patients with normal body Time: Within 14 days after enrollmentDescription: Proportion of patients without dyspnea
Measure: Proportion of patients without dyspnea Time: Within 14 days after enrollmentDescription: Proportion of patients without cough
Measure: Proportion of patients without cough Time: Within 14 days after enrollmentDescription: Proportion of patients without oxygen treatment
Measure: Proportion Time: Within 14 days after enrollmentDescription: The negative conversion rate of new coronavirus nucleic acid
Measure: The negative conversion rate of new coronavirus nucleic acid Time: Within 14 days after enrollmentDescription: Proportion of patients hospitalized/hospitalized in ICU
Measure: Proportion Time: within 28 days after enrollmentDescription: Frequency of serious adverse drug events.
Measure: Frequency of serious adverse drug events. Time: within 28 days after enrollmentAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports